New antibiotic offers hope for more effective Lyme disease treatment

Lyme disease, a disease transmitted when deer ticks feed on infected animals like deer and rodents, and then...

Early gut microbiota linked to food sensitivities in infants

A study led by Hiroshi Ohno at the RIKEN Center for Integrative Medical Sciences (IMS) recently showed that...

CDC confirms black-legged ticks can cause red meat allergy in humans

A woman in Maine developed a dangerous meat allergy after a black-legged tick bite—prompting the CDC to rethink...

Gut immune cells linked to worsening rheumatoid arthritis

After spending years tracing the origin and migration pattern of an unusual type of immune cell in mice,...

Breakthrough discovery unveils potential treatment for hepatitis B

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able...

NIH funds research to develop a game-changing HIV diagnostic tool

As of the end of 2023, nearly 40 million people worldwide were living with HIV, including approximately 1.2...

Growth factor cocktail could reverse deadly effects of anthrax toxin

Anthrax, an infectious disease caused by the bacterium Bacillus anthracis, is often treatable in its early stages. But...

Understanding FDA’s complaint reporting systems

If you have a complaint about a product regulated by the U.S. Food and Drug Administration (FDA), the...

Material from nasal lavage provides a basis for assessing COPD

Early diagnosis of COPD, chronic obstructive pulmonary disease, increases the quality of life of the patient and the...

Researchers develop mouse model to study neutrophilic asthma

A better understanding of inflammation and lung immunity over the past two decades has led to new, innovative...

Synthetic microbiome therapy offers new hope against C. difficile infections

A synthetic microbiome therapy, tested in mice, protects against severe symptoms of a gut infection that is notoriously...

New human antibody shows promise for Ebola virus treatment

New research led by scientists at La Jolla Institute for Immunology (LJI) reveals the workings of a human...

Scientists link emulsifiers in processed foods to allergy and immune disorders

From your pantry to your gut: Scientists reveal how everyday food additives could silently fuel allergies, gut disorders,...

Current antivirals not successful in treating severe H5N1 bird flu infections

As the H5N1 avian influenza outbreak continues, scientists are working to better understand the virus's threat to human...

New study reveals hidden spread of C. diff in intensive care units

One of the most common health care-associated infections spreads within intensive care units (ICUs) more than three times...

Daily peanut doses help adults overcome severe allergies

The first clinical trial to test whether adults allergic to peanuts can be desensitized has shown great success...

Clinical trial of vaccine candidate to prevent Lassa fever begins enrollment

A National Institutes of Health (NIH)-sponsored clinical trial of a candidate vaccine to prevent Lassa fever has begun...

Gut Microbiome and Allergic Diseases: A Revolutionary Paradigm for Prevention and Treatment

The human gastrointestinal tract harbors a complex ecosystem of trillions of microorganisms that collectively constitute the gut microbiome,...

Asthma and antibiotic use increase the likelihood of revision sinus surgery

The probability of revision sinus surgery including the removal of nasal polyps is higher if the patient has...

Feeding infants diverse foods early may cut allergy risk, study reveals

New research reveals that feeding infants a variety of foods in their first year can help prevent allergies...

Beckman coulter’s new basophil activation test for allergies

Innovation Follows $1 Million FARE Award.

Image Credit: Beckman Coulter Life Sciences

Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, introduces the Next-Generation Basophil Activation Test (BAT) for research use only to more effectively characterize food allergies without exposure to potentially harmful allergens.

Approximately 220 million people globally suffer from at least one food allergy. Most food allergies and treatment efficacies are currently determined through a dated and rigorous Oral Food Challenge (OFC), exposing a patient to gradual amounts of foods to determine if they have a reaction, which could include anaphylaxis in some situations. The new BAT test eliminates that risk, testing for multiple allergens at once through a blood draw — saving hours of food testing and exposure to potentially harmful reactions.

This offers a groundbreaking alternative in allergy testing, removing patient obstacles and reducing ethical concerns associated with direct allergen exposure in vulnerable participants,”

Jean-Marc Busnel, PhD, Principal Investigator and Senior Staff Research Scientist, Beckman Coulter Life Sciences

“For too long these concerns have limited critical advancements, putting people at risk of not having access to life-saving treatment options should an allergic reaction occur. By removing these barriers, this test unlocks an opportunity to finally expand food allergy drug development and research. This reinforces our mission at Beckman Coulter Life Sciences to deliver tools that empower clinicians and improve patient outcomes.”

The innovation follows the FARE (Food Allergy Research and Education) Innovation Award Diagnostic Challenge which Beckman Coulter Life Sciences received in 2022. The $1 million award helps foster the development of improved testing methods in the field of food allergies.

“At FARE, we have prioritized supporting the development of safer alternatives to oral food challenges that can expose patients to risk and induce anxiety,” said Sung Poblete, PhD, RN, CEO of FARE. “The introduction of this next-generation Basophil Activation Test marks a significant advancement, moving diagnostic innovation from the bench toward future clinical application, paving the way for safer, more accessible food allergy research while offering the opportunity to stimulate progress and we are excited about the promise it holds for research and development.”

BAT are functional assays measuring basophil activation in response to specific allergens or other stimuli.

By leveraging dry technology to overcome traditional BAT challenges, standardization is enabled with conjugated antibodies and allergens pre-mixed and dried down together in a single tube with only 4 pipetting steps. Negative and positive controls can also be included, all without the need for compensation or centrifugation, and is compatible with any flow cytometer.

While BAT has been around for more than 30 years and provides valuable insights in the study of allergies, its adoption has been limited due to the perceived complexity and lack of reproducibility associated with the assay. The use of dry reagents can support overcoming those challenges.

The test offers unmatched flexibility with customizable dried down allergens, antibodies, and concentrations available through Custom Design Service from Beckman Coulter Life Sciences.

Image Credit: Beckman Coulter Life Sciences

About Beckman Coulter Life Sciences

Time is the most critical facet in the laboratory today:  time to get life-saving therapies to patients faster; reclaiming time by automating tedious manual workflows; and saving time otherwise spent addressing erroneous or complex results.

At Beckman Coulter Life Sciences, we are partners in time. We accelerate answers to critical questions through the power of efficiency, saving hours from some workflows and delivering reliable results in centrifugation, flow cytometry, genomic solutions, particle analysis/counters, and liquid handlers.

We develop innovations for scientists by scientists, with many of our 3,300+ global colleagues coming from the laboratory with a deep understanding of today’s challenges and complexities. We’re passionate about translating science in partnership with our customers, and our customizable, accessible and sustainable solutions empower them with intuitive workflow efficiencies.

Time and again customers put their trust in us, with 400,000+ of our built-to-last products currently delivering results in labs worldwide – all backed by our dependable service and application experts offering educational insights and tailored support.

It’s all part of our time-tested approach since 1935 to bring meaningful innovations at the speed of life—and we’re just beginning. Working together, let’s advance human health for a better tomorrow!

Get to know us by clicking here and by following us on LinkedIn.

Source:

Beckman Coulter Life Sciences


Source: http://www.news-medical.net/news/20250408/Beckman-Coulter-Life-Sciences-launches-safer-Next-Generation-Basophil-Activation-Test-to-improve-expedite-allergy-research.aspx

Inline Feedbacks
View all comments
guest